Himanshu Garg1, Rose Yeh2, Douglas M Watts3, Tugba Mehmetoglu-Gurbuz4, Robert Resendes5, Bruce Parsons5, Fernando Gonzales5, Anjali Joshi6. 1. Center of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center, 5001 El Paso Dr, El Paso, TX, 79905, USA. hgarg75@gmail.com. 2. Paul L Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA. 3. Department of Biological Sciences, University of Texas at El Paso, El Paso, TX, USA. 4. Center of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center, 5001 El Paso Dr, El Paso, TX, 79905, USA. 5. Department of Public Health, City of El Paso, El Paso, TX, USA. 6. Center of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center, 5001 El Paso Dr, El Paso, TX, 79905, USA. ajoshi145@yahoo.com.
Abstract
BACKGROUND: Recent outbreaks of Zika Virus (ZIKV) infection and associated microcephaly has raised multiple scientific questions. The close antigenic relatedness between flaviviruses makes diagnosis of specific infection difficult. This relatedness also raises the potential of Antibody Dependent Enhancement (ADE) via cross reactive antibodies to flaviviruses like West Nile Virus (WNV) and Dengue Virus (DENV). Asymptomatic WNV infections are endemic throughout the US creating a large proportion of the population that is seropositive for WNV antibodies. Whether these sero-positive individuals potentially carry ZIKV enhancing antibodies remains unknown. RESULTS: Serum samples obtained from human subjects with symptomatic or asymptomatic WNV infection from a WNV endemic region in Texas were tested for their ability to enhance or neutralize ZIKV infection. Sero-surveillance data demonstrated a ~ 7% prevalence for WNV antibodies in the population. Sera from both symptomatic and asymptomatic WNV seropositive donors effectively neutralized WNV and to some extent DENV infection. Interestingly, WNV+ sera failed to inhibit ZIKV while significantly enhancing infection. Conversely, ZIKV specific sera effectively neutralized ZIKV, with ADE only evident at lower concentrations. The enhancement of ZIKV via WNV antibody positive sera was likely due to non-neutralizing Envelope (E) antibodies as seen with monoclonal ZIKV E antibodies. CONCLUSIONS: Overall, our findings suggest that WNV antibodies in the sera significantly enhance ZIKV infection in Fc receptor positive cells with limited neutralization activity. Further studies in more relevant models of ADE will be needed to confirm the relevance of these findings in vivo.
BACKGROUND: Recent outbreaks of Zika Virus (ZIKV) infection and associated microcephaly has raised multiple scientific questions. The close antigenic relatedness between flaviviruses makes diagnosis of specific infection difficult. This relatedness also raises the potential of Antibody Dependent Enhancement (ADE) via cross reactive antibodies to flaviviruses like West Nile Virus (WNV) and Dengue Virus (DENV). Asymptomatic WNV infections are endemic throughout the US creating a large proportion of the population that is seropositive for WNV antibodies. Whether these sero-positive individuals potentially carry ZIKV enhancing antibodies remains unknown. RESULTS: Serum samples obtained from human subjects with symptomatic or asymptomatic WNV infection from a WNV endemic region in Texas were tested for their ability to enhance or neutralize ZIKV infection. Sero-surveillance data demonstrated a ~ 7% prevalence for WNV antibodies in the population. Sera from both symptomatic and asymptomatic WNV seropositive donors effectively neutralized WNV and to some extent DENV infection. Interestingly, WNV+ sera failed to inhibit ZIKV while significantly enhancing infection. Conversely, ZIKV specific sera effectively neutralized ZIKV, with ADE only evident at lower concentrations. The enhancement of ZIKV via WNV antibody positive sera was likely due to non-neutralizing Envelope (E) antibodies as seen with monoclonal ZIKV E antibodies. CONCLUSIONS: Overall, our findings suggest that WNV antibodies in the sera significantly enhance ZIKV infection in Fc receptor positive cells with limited neutralization activity. Further studies in more relevant models of ADE will be needed to confirm the relevance of these findings in vivo.
Authors: Scott A Smith; Usha K Nivarthi; Ruklanthi de Alwis; Nurgun Kose; Gopal Sapparapu; Robin Bombardi; Kristen M Kahle; Jennifer M Pfaff; Sherri Lieberman; Benjamin J Doranz; Aravinda M de Silva; James E Crowe Journal: J Virol Date: 2015-10-28 Impact factor: 5.103
Authors: Susana V Bardina; Paul Bunduc; Shashank Tripathi; James Duehr; Justin J Frere; Julia A Brown; Raffael Nachbagauer; Gregory A Foster; David Krysztof; Domenico Tortorella; Susan L Stramer; Adolfo García-Sastre; Florian Krammer; Jean K Lim Journal: Science Date: 2017-03-30 Impact factor: 47.728
Authors: Priscila M S Castanha; Eduardo J M Nascimento; Cynthia Braga; Marli T Cordeiro; Otávio V de Carvalho; Leila R de Mendonça; Elisa A N Azevedo; Rafael F O França; Rafael Dhalia; Ernesto T A Marques Journal: J Infect Dis Date: 2017-03-01 Impact factor: 5.226
Authors: Mark R Duffy; Tai-Ho Chen; W Thane Hancock; Ann M Powers; Jacob L Kool; Robert S Lanciotti; Moses Pretrick; Maria Marfel; Stacey Holzbauer; Christine Dubray; Laurent Guillaumot; Anne Griggs; Martin Bel; Amy J Lambert; Janeen Laven; Olga Kosoy; Amanda Panella; Brad J Biggerstaff; Marc Fischer; Edward B Hayes Journal: N Engl J Med Date: 2009-06-11 Impact factor: 91.245
Authors: Thomas Langerak; Noreen Mumtaz; Vera I Tolk; Eric C M van Gorp; Byron E Martina; Barry Rockx; Marion P G Koopmans Journal: PLoS Pathog Date: 2019-04-18 Impact factor: 6.823
Authors: Mohammed A H Farouq; Reinaldo Acevedo; Valerie A Ferro; Paul A Mulheran; Mohammed M Al Qaraghuli Journal: Int J Mol Sci Date: 2022-05-28 Impact factor: 6.208
Authors: Francesca Falconi-Agapito; Karen Kerkhof; Xiomara Merino; Johan Michiels; Marjan Van Esbroeck; Koen Bartholomeeusen; Michael Talledo; Kevin K Ariën Journal: Front Immunol Date: 2021-07-05 Impact factor: 7.561